Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may predict IBD Flare-Ups

NCT ID NCT04535882

Knowledge-focused Sponsor: Showa Inan General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study is looking at whether a substance in the blood called LRG can help doctors tell how active ulcerative colitis or Crohn's disease is in the gut. Researchers will measure LRG levels in 300 people who might have these conditions and compare them with what is seen during a colonoscopy. The goal is to see if LRG could be a simple blood test to monitor disease activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

673 people

The number who actually took part.

Started

Oct 2020

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

In total, a consecutive cohort of 300 patients with possible UC or CD will be enrolled in this study at our hospital.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients whom possible UC or Crohn disease was suspected Exclusion Criteria: * other autoimmune diseases * acute or chronic renal failure * chronic heart diseases * liver cirrhosis * cancer * acute or chronic systemic infections * ischemic colitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LRG levels

Contacts and locations

Locations

  • Showa Inan General Hospital

    Komagane, Nagano, 399-4117, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.